|
1
|
Ahmad R, Singh JK, Wunnava A, Al-Obeed O,
Abdulla M and Srivastava SK: Emerging trends in colorectal cancer:
Dysregulated signaling pathways (Review). Int J Mol Med. 47:142021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Alsanea N, Abduljabbar AS, Alhomoud S,
Ashari LH, Hibbert D and Bazarbashi S: Colorectal cancer in Saudi
Arabia: Incidence, survival, demographics and implications for
national policies. Ann Saudi Med. 35:196–202. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bazarbashi S, Al Eid H and Minguet J:
Cancer Incidence in Saudi Arabia: 2012 Data from the Saudi cancer
registry. Asian Pac J Cancer Prev. 18:2437–2444. 2017.PubMed/NCBI
|
|
4
|
Riihimäki M, Hemminki A, Sundquist J and
Hemminki K: Patterns of metastasis in colon and rectal cancer. Sci
Rep. 6:297652016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Andersen NN and Jess T: Has the risk of
colorectal cancer in inflammatory bowel disease decreased? World J
Gastroenterol. 19:7561–7568. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu Y, Zheng Y, Dai M, Wu J, Yu B, Zhang H,
Kong W, Wu H and Yu X: Snail2 induced E-cadherin suppression and
metastasis in lung carcinoma facilitated by G9a and HDACs. Cell Adh
Migr. 13:285–292. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaszak I, Witkowska-Piłaszewicz O,
Niewiadomska Z, Dworecka-Kaszak B, Ngosa Toka F and Jurka P: Role
of cadherins in cancer-a review. Int J Mol Sci. 21:76242020.
View Article : Google Scholar
|
|
8
|
Kim WK, Kwon Y, Jang M, Park M, Kim J, Cho
S, Jang DG, Lee WB, Jung SH, Choi HJ, et al: β-catenin activation
down-regulates cell-cell junction-related genes and induces
epithelial-to-mesenchymal transition in colorectal cancers. Sci
Rep. 9:184402019. View Article : Google Scholar
|
|
9
|
Kufe DW: Mucins in cancer: Function,
prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Colpitts TL, Billing P, Granados E, Hayden
M, Hodges S, Roberts L, Russell J, Friedman P and Stroupe S:
Identification and immunohistochemical characterization of a
mucin-like glycoprotein expressed in early stage breast carcinoma.
Tumour Biol. 23:263–278. 2002. View Article : Google Scholar
|
|
11
|
Miksicek RJ, Myal Y, Watson PH, Walker C,
Murphy LC and Leygue E: Identification of a novel breast- and
salivary gland-specific, mucin-like gene strongly expressed in
normal and tumor human mammary epithelium. Cancer Res.
62:2736–2740. 2002.PubMed/NCBI
|
|
12
|
Skliris GP, Hubé F, Gheorghiu I, Mutawe
MM, Penner C, Watson PH, Murphy LC, Leygue E and Myal Y: Expression
of small breast epithelial mucin (SBEM) protein in tissue
microarrays (TMAs) of primary invasive breast cancers.
Histopathology. 52:355–369. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ayerbes MV, Diaz-Prado S, Ayude D, Campelo
RG, Iglesias P, Haz M, Medina V, Gallegos I and Quindós M: In
silico and in vitro analysis of small breast epithelial mucin as a
marker for bone marrow micrometastasis in breast cancer. Adv Exp
Med Biol. 617:331–339. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Valladares-Ayerbes M, Iglesias-Diaz P,
Diaz-Prado S, Ayude D, Medina V, Haz M, Reboredo M, Antolín S,
Calvo L and Antón-Aparicio LM: Diagnostic accuracy of small breast
epithelial mucin mRNA as a marker for bone marrow micrometastasis
in breast cancer: A pilot study. J Cancer Res Clin Oncol.
135:1185–1195. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weigelt B, Verduijn P, Bosma AJ, Rutgers
EJ, Peterse HL and van't Veer LJ: Detection of metastases in
sentinel lymph nodes of breast cancer patients by multiple mRNA
markers. Br J Cancer. 90:1531–1537. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu ZZ, Xie XD, Qu SX, Zheng ZD and Wang
YK: Small breast epithelial mucin (SBEM) has the potential to be a
marker for predicting hematogenous micrometastasis and response to
neoadjuvant chemotherapy in breast cancer. Clin Exp Metastasis.
27:251–259. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li QH, Liu ZZ, Ge YN, Liu X, Xie XD, Zheng
ZD, Ma YH and Liu B: Small breast epithelial mucin promotes the
invasion and metastasis of breast cancer cells via promoting
epithelial-to-mesenchymal transition. Oncol Rep. 44:509–518. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang Z, Li C, Kang B, Gao G, Li C and
Zhang Z: GEPIA: A web server for cancer and normal gene expression
profiling and interactive analyses. Nucleic Acids Res. 45:W98–W102.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chandrashekar DS, Bashel B, Balasubramanya
SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi BVSK and
Varambally S: UALCAN: A portal for facilitating tumor subgroup gene
expression and survival analyses. Neoplasia. 19:649–658. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Al-Khayal K, Vaali-Mohammed MA, Elwatidy
M, Bin Traiki T, Al-Obeed O, Azam M, Khan Z, Abdulla M and Ahmad R:
A novel coordination complex of platinum (PT) induces cell death in
colorectal cancer by altering redox balance and modulating MAPK
pathway. BMC Cancer. 20:6852020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vishnubalaji R, Hamam R, Abdulla MH,
Mohammed MA, Kassem M, Al-Obeed O, Aldahmash A and Alajez NM:
Genome-wide mRNA and miRNA expression profiling reveal multiple
regulatory networks in colorectal cancer. Cell Death Dis.
6:e16142015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hardwick JM and Soane L: Multiple
functions of Bcl2 family proteins. Cold Spring Harb Prospect Biol.
5:a0087222013.
|
|
23
|
Baig S, Seevasant I, Mohamad J, Mukheem A,
Huri HZ and Kamarul T: Potential of apoptotic pathway-targeted
cancer therapeutic research: Where do we stand? Cell Death Dis.
7:e20582016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fares J, Fares MY, Khachfe HH, Salhab HA
and Fares Y: Molecular principles of metastasis: A hallmark of
cancer revisited. Sig Transduct Target Ther. 5:282020. View Article : Google Scholar
|
|
25
|
Valenta T, Hausmann G and Basler K: The
many faces and functions of β-catenin. EMBO J. 31:2714–2736. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Siegel RL, Miller KD, Goding Sauer A,
Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA and Jemal
A: Colorectal cancer statistics, 2020. CA Cancer J Clin.
70:145–164. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Biller LH and Schrag D: Diagnosis and
treatment of metastatic colorectal cancer: A review. JAMA.
325:669–685. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Conley SJ, Bosco EE, Tice DA,
Hollingsworth RE, Herbst R and Xiao Z: HER2 drives Mucin-like 1 to
control proliferation in breast cancer cells. Oncogene.
35:4225–4234. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
King RJ, Yu F and Singh PK: Genomic
alterations in mucins across cancers. Oncotarget. 8:67152–67168.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Aziz MA, AlOtaibi M, AlAbdulrahman A,
AlDrees M and AlAbdulkarim I: Mucin family genes are downregulated
in colorectal cancer patients. J Carcinogene Mutagene S10:.
009:2014.
|
|
31
|
Ramesh P and Medema JP: BCL-2 family
deregulation in colorectal cancer: Potential for BH3 mimetics in
therapy. Apoptosis. 25:305–320. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nieto MA, Huang RY, Jackson RA and Thiery
JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rajabi H, Alam M, Takahashi H, Kharbanda
A, Guha M, Ahmad R and Kufe D: MUC1-C oncoprotein activates the
ZEB1/miR-200c regulatory loop and epithelial-mesenchymal
transition. Oncogene. 33:1680–1689. 2014. View Article : Google Scholar
|
|
36
|
Takahashi H, Jin C, Rajabi H, Pitroda S,
Alam M, Ahmad R, Raina D, Hasegawa M, Suzuki Y, Tagde A, et al:
MUC1-C activates the TAK1 inflammatory pathway in colon cancer.
Oncogene. 34:5187–5197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ahmad R, Raina D, Trivedi V, Ren J, Rajabi
H, Kharbanda S and Kufe D: MUC1 oncoprotein activates the IkappaB
kinase beta complex and constitutive NF-kappaB signalling. Nat Cell
Biol. 9:1419–1427. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ahmad R, Raina D, Joshi MD, Kawano T,
Kharbanda S and Kufe D: MUC1-C oncoprotein functions as a direct
activator of the nuclear factor-kappaB p65 transcription factor.
Cancer Res. 69:7013–7021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu C, Li Y, Semenov M, Han C, Baeg GH,
Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin
phosphorylation/degradation by a dual-kinase mechanism. Cell.
108:837–847. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fang D, Hawke D, Zheng Y, Xia Y,
Meisenhelder J, Nika H, Mills GB, Kobayashi R, Hunter T and Lu Z:
Phosphorylation of beta-catenin by AKT promotes beta-catenin
transcriptional activity. J Biol Chem. 282:11221–11229. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sánchez-Tilló E, de Barrios O, Siles L,
Cuatrecasas M, Castells A and Postigo A: β-catenin/TCF4 complex
induces the epithelial-to-mesenchymal transition (EMT)-activator
ZEB1 to regulate tumor invasiveness. Proc Natl Acad Sci USA.
108:19204–19209. 2011. View Article : Google Scholar
|
|
42
|
Pai P, Rachagani S, Dhawan P and Batra SK:
Mucins and Wnt/β-catenin signaling in gastrointestinal cancers: An
unholy nexus. Carcinogenesis. 37:223–232. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Huang L, Chen D, Liu D, Yin L, Kharbanda S
and Kufe D: MUC1 oncoprotein blocks glycogen synthase kinase
3beta-mediated phosphorylation and degradation of beta-catenin.
Cancer Res. 65:10413–10422. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wörthmüller J and Rüegg C: The crosstalk
between FAK and Wnt signaling pathway in cancer and its therapeutic
implication. Int J Mol Sci. 21:91072020. View Article : Google Scholar
|
|
45
|
Gao C, Chen G, Kuan SF, Zhang DH,
Schlaepfer DD and Hu J: FAK/PYK2 promotes the Wnt/β-catenin pathway
and intestinal tumorigenesis by phosphorylating GSK3β. Elife.
4:e100722015. View Article : Google Scholar
|
|
46
|
Rougier P and Mitry E: Review of the role
of CPT-11 in the treatment of colorectal cancer. Clin Colorectal
Cancer. 1:87–94. 2001. View Article : Google Scholar
|
|
47
|
Vanhoefer U, Harstrick A, Achterrath W,
Cao S, Seeber S and Rustum YM: Irinotecan in the treatment of
colorectal cancer: Clinical overview. J Clin Oncol. 19:1501–1518.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Xu Y and Villalona-Calero MA: Irinotecan:
Mechanisms of tumor resistance and novel strategies for modulating
its activity. Ann Oncol. 13:1841–1851. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Abal M, Bras-Goncalves R, Judde JG, Fsihi
H, De Cremoux P, Louvard D, Magdelenat H, Robine S and Poupon MF:
Enhanced sensitivity to irinotecan by Cdk1 inhibition in the
p53-deficient HT29 human colon cancer cell line. Oncogene.
23:1737–1744. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Tuy HD, Shiomi H, Mukaisho KI, Naka S,
Shimizu T, Sonoda H, Mekata E, Endo Y, Kurumi Y, Sugihara H, et al:
ABCG2 expression in colorectal adenocarcinomas may predict
resistance to irinotecan. Oncol Lett. 12:2752–2760. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Erdem ZN, Schwarz S, Drev D, Heinzle C,
Reti A, Heffeter P, Hudec X, Holzmann K, Grasl-Kraupp B, Berger W,
et al: Irinotecan upregulates fibroblast growth factor receptor 3
expression in colorectal cancer cells, which mitigates irinotecan
induced apoptosis. Transl Oncol. 10:332–339. 2017. View Article : Google Scholar : PubMed/NCBI
|
